Across TCGA pan-cancer cohorts, PRRC2A mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PRRC2A data layer compared with 24 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PRRC2A mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated PRRC2A expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where PRRC2A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.268	0.540	.001	22	view →
CCRCC	OS	Median	II,III,IV	0.843	0.630	.009	5	view →
LUAD	DFS	Median	All	0.686	0.907	.047	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: PRRC2A tumor-vs-normal RNA expression · all PRRC2A data types